Inspira Technologies OXY B.H.N. Ltd. reaffirmed $49.5 million in purchase orders, with payments to start in 2026. The company is working with its distribution partner to advance orders and align with regulatory sequencing. Inspira is coordinating with regulators and funding partners for execution and deployment, reducing execution risk. The company’s INSPIRA™ ART100 system is FDA-cleared for cardiopulmonary bypass and ECMO procedures, with plans for the next-gen INSPIRA ART500. Inspira is also developing HYLA™, a blood sensor platform for continuous monitoring. Forward-looking statements highlight expectations for future milestones and market rollout in 2026.

Read more at GlobeNewswire: Inspira Technologies Reaffirms $49.5 Million in Binding